- Home
- ANGH vs NRXP Comparison
ANGH vs NRXP Comparison
Compare ANGH & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGH
- NRXP
- Stock Information
- Founded
- ANGH 2012
- NRXP 2015
- Country
- ANGH United Arab Emirates
- NRXP United States
- Employees
- ANGH N/A
- NRXP N/A
- Industry
- ANGH Telecommunications Equipment
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ANGH Consumer Discretionary
- NRXP Health Care
- Exchange
- ANGH Nasdaq
- NRXP Nasdaq
- Market Cap
- ANGH 32.1M
- NRXP 58.5M
- IPO Year
- ANGH N/A
- NRXP N/A
- Fundamental
- Price
- ANGH $0.41
- NRXP $2.81
- Analyst Decision
- ANGH
- NRXP Strong Buy
- Analyst Count
- ANGH 0
- NRXP 4
- Target Price
- ANGH N/A
- NRXP $28.50
- AVG Volume (30 Days)
- ANGH 2.8M
- NRXP 134.9K
- Earning Date
- ANGH 08-05-2025
- NRXP 08-13-2025
- Dividend Yield
- ANGH N/A
- NRXP N/A
- EPS Growth
- ANGH N/A
- NRXP N/A
- EPS
- ANGH N/A
- NRXP N/A
- Revenue
- ANGH $78,093,405.00
- NRXP N/A
- Revenue This Year
- ANGH N/A
- NRXP N/A
- Revenue Next Year
- ANGH N/A
- NRXP $230.95
- P/E Ratio
- ANGH N/A
- NRXP N/A
- Revenue Growth
- ANGH 88.72
- NRXP N/A
- 52 Week Low
- ANGH $0.40
- NRXP $1.10
- 52 Week High
- ANGH $0.98
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- ANGH 41.92
- NRXP 35.57
- Support Level
- ANGH $0.44
- NRXP $2.89
- Resistance Level
- ANGH $0.71
- NRXP $3.15
- Average True Range (ATR)
- ANGH 0.08
- NRXP 0.14
- MACD
- ANGH -0.00
- NRXP -0.04
- Stochastic Oscillator
- ANGH 1.87
- NRXP 7.27
About ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.